NCT04530552View on ClinicalTrials.gov

Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

July 23, 2021

Primary Completion Date

November 6, 2024

Study Completion Date

January 31, 2027

Conditions
Localized Prostate CarcinomaProstate AdenocarcinomaStage I Prostate Cancer AJCC v8Stage II Prostate Cancer AJCC v8
Interventions
DRUG

Apalutamide

Given PO

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (5)

20037

George Washington University Medical Center, Washington D.C.

20892

NCI - Center for Cancer Research, Bethesda

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

85719

University of Arizona Cancer Center - Prevention Research Clinic, Tucson

90033

USC / Norris Comprehensive Cancer Center, Los Angeles

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH